![Frank Grosveld](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Frank Grosveld
Fondatore presso Harbour Antibodies BV
Profilo
Frank Grosveld is the founder of Harbour Antibodies BV, which was founded in 2006.
He holds the title of Director & Chief Scientific Officer at Harbour Antibodies BV.
Currently, Dr. Grosveld is a Professor and Head of Cell Biology at The Royal Netherlands Academy of Arts & Sciences, a position he has held since 2013.
Posizioni attive di Frank Grosveld
Società | Posizione | Inizio |
---|---|---|
Harbour Antibodies BV
![]() Harbour Antibodies BV Medical/Nursing ServicesHealth Services Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands. | Fondatore | 01/01/2006 |
The Royal Netherlands Academy of Arts & Sciences
![]() The Royal Netherlands Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Netherlands Academy of Arts & Sciences provides research services in the field of science and art. The private company is based in Amsterdam, Netherlands and has subsidiaries in Netherlands. The CEO of the Dutch company is Wilma de Koning. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Harbour Antibodies BV
![]() Harbour Antibodies BV Medical/Nursing ServicesHealth Services Harbour Antibodies BV engages in the production of antibodies and VH domains for therapy. The firm develops two types of human immunoglobulin gene transgenic mice such as mice that generate conventional tetrameric antibodies comprising two heavy and two light immunoglobulin chains (H2L2); and alternatively, mice that generate heavy chain only antibodies comprising two immunoglobulin heavy chains with no light chains (HCAbs). The company was founded by Frank Grosveld in 2006 and is headquartered in Rotterdam, the Netherlands. | Health Services |
The Royal Netherlands Academy of Arts & Sciences
![]() The Royal Netherlands Academy of Arts & Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Netherlands Academy of Arts & Sciences provides research services in the field of science and art. The private company is based in Amsterdam, Netherlands and has subsidiaries in Netherlands. The CEO of the Dutch company is Wilma de Koning. | Commercial Services |
- Borsa valori
- Insiders
- Frank Grosveld